A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations



Status:Recruiting
Conditions:Prostate Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/31/2019
Start Date:April 5, 2018
End Date:June 17, 2021
Contact:Study Contact
Email:JNJ.CT@sylogent.com
Phone:844-434-4210

Use our guide to learn which trials are right for you!

A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations

The purpose of this study is to identify the recommended Phase 2 dose (RP2D) and schedule of
erdafitinib in combination with JNJ-63723283 (Phase 1b) and to evaluate the safety and
clinical activity of erdafitinib alone and in combination with JNJ-63723283 (Phase 2).

This open-label (all people know identity of intervention) and multicenter (when more than
one hospital or medical school team work on a medical research study) study of erdafitinib
plus JNJ-63723283 in participants with advanced urothelial cancer with selected fibroblast
growth factor receptor (FGFR) gene alterations who have progressed on or after one or more
prior lines of systemic therapy, will consists of 2 parts. Part 1 (Phase 1b: Dose Escalation)
will establish recommended Phase 2 dose (RP2D) for erdafitinib in combination with
JNJ-63723283, and Part 2 (Phase 2: Dose Expansion) will evaluate safety and efficacy of RP2D.
The study will be conducted in 3 phases: screening phase, treatment phase, and follow-up
phase. Study evaluations include efficacy, pharmacokinetics, pharmacodynamics,
immunogenicity, biomarkers, and safety.

Inclusion Criteria:

- Histologic demonstration of transitional cell carcinoma of the urothelium. Minor
components (less than [<] 50 percent [%] overall) of variant histology such as
glandular or squamous differentiation, or evolution to more aggressive phenotypes such
as sarcomatoid or micropapillary change are acceptable

- Stage IV disease

- Documented progression of disease per Response Evaluation Criteria in Solid Tumors
(RECIST) 1.1, defined as any progression that requires a change in treatment, prior to
randomization

- Prior systemic therapy: (a) Phase 1b: Any number of lines of prior therapy; (b) Phase
2: Progressed after 1 or 2 lines of prior chemotherapy

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) grade of: 0 or 1

Exclusion Criteria:

- Treatment with any other investigational agent or participation in another clinical
study with therapeutic intent within 30 days prior to Cycle 1 Day 1. For Phase 1b,
participants who have received the following prior antitumor therapy: received
nitrosoureas and mitomycin C within 6 weeks

- Chemotherapy within 3 weeks of Cycle 1 Day 1

- Prior anti-programmed death receptor-1 (PD-1), anti-programmed death ligand-1 (PD-L1),
or anti-programmed death ligand-2 (PD-L2) therapy

- Active malignancies (that is, requiring treatment change in the last 24 months) other
than urothelial cancer (except skin cancers within the last 24 months that are
considered completely cured)

- Symptomatic central nervous system metastases
We found this trial at
18
sites
New York, New York 10021
?
mi
from
New York, NY
Click here to add this to my saved trials
Iowa City, Iowa 52242
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Aurora, Colorado 80012
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Bethlehem, Pennsylvania
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
1021 Morehead Medical Drive
Charlotte, North Carolina 28204
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Fort Worth, Texas 76104
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
7 Žarkoŭski Street
Gomel, 24602
?
mi
from
Gomel,
Click here to add this to my saved trials
30 Prospect Ave
Hackensack, New Jersey 07601
(201) 996-2000
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
?
mi
from
Hershey, PA
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Las Vegas, Nevada 89135
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Louisville, Kentucky 40207
?
mi
from
Louisville, KY
Click here to add this to my saved trials
5900 Lake Wright Dr
Norfolk, Virginia 23502
(757) 466-8683
Virginia Oncology Associates Virginia Oncology Associates is an oncology and hematology practice of physicians, specializing...
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
Rockville, Maryland 20850
?
mi
from
Rockville, MD
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
4126 North Holland Sylvania Road
Toledo, Ohio 43623
?
mi
from
Toledo, OH
Click here to add this to my saved trials
White Plains, New York 10601
?
mi
from
White Plains, NY
Click here to add this to my saved trials